Immuneering Welcomes Dr. Igor Matushansky as Chief Medical Officer to Drive Oncology Innovation

Immuneering (Nasdaq: IMRX) has announced the appointment of Dr. Igor Matushansky, MD, PhD, as its Chief Medical Officer, marking a significant step in advancing its oncology pipeline. Dr. Matushansky will oversee the company’s ongoing Phase 2a clinical trial of IMM-1-104, a next-generation therapy targeting pancreatic cancer, lung cancer, and melanoma. His leadership will be crucial as Immuneering prepares to launch a pivotal Phase 3 trial in pancreatic cancer, aiming to deliver a more effective and better-tolerated treatment option for patients.

With a distinguished career spanning Ipsen, Novartis, Daiichi Sankyo, and Hookipa Pharma, Dr. Matushansky brings deep expertise in oncology drug development and translational medicine. He has played a key role in groundbreaking advancements in cancer therapeutics, including the approval of NALIRIFOX for first-line pancreatic cancer. His dedication to improving both efficacy and patient quality of life aligns with Immuneering’s mission to redefine oncology care. As he steps into this leadership role, his vision and experience are set to accelerate the company’s clinical programs and future innovations.